The Oncology Burden Of Proof: Learning From The PD-1 Market
The Oncology Burden Of Proof: Learning From The PD-1 Market
$200.00
In Vivo interviews Eva Marchese, VP at consulting group Charles River Associates, for insights into the challenges facing the PD-1/LD1 European market’s reimbursement and access schemes for IO products. Gain insights into the sustainability obstacles for immuno-oncology products in this vital interview.
Author: Lucie Ellis
Publisher: InVivo
- Description
With an increase in the number of immuno-oncology drugs coming to market, the question of sustainability cannot be ignored. Biopharma companies are looking for reimbursement deals that reflect the value of their innovations, while healthcare systems are concerned about rising costs. Through an examination of the PD-1/LD1 market for Europe, consulting firm Charles River Associates takes a deeper look into the reimbursement and access issues that novel immunotherapies face, focusing on three crucial areas. Find out what they are in this essential In Vivo article.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
US FDA May Largely Avoid House Democrats’ Investigation Agenda 
Sign up to the